Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings COSMOS Pharmaceutical Corporation: Strengths and Weaknesses

  • The company's MSCI ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Highlights: COSMOS Pharmaceutical Corporation
  • The company's profit outlook over the next few years is a strong asset.
  • The company returns high margins, thereby supporting business profitability.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: COSMOS Pharmaceutical Corporation
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Most analysts recommend that the stock should be sold or reduced.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

COSMOS Pharmaceutical Corporation SectorJapan

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

COSMOS Pharmaceutical Corporation SectorJapan

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

COSMOS Pharmaceutical Corporation SectorJapan

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

COSMOS Pharmaceutical Corporation SectorJapan

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

COSMOS Pharmaceutical Corporation SectorJapan

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.05B
BBB
6.47B
BBB
3.31B
AA
2.75B
AA
2.21B
B
1.38B -
1.36B -
BBB
- - - - -
468M -
BBB
- - - - -
363M
AA
-
331M - - - - - - -
Average 2.17B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Stocks
  3. 3349 Stock
  4. Ratings COSMOS Pharmaceutical Corporation